国内丙型肝炎病毒(HCV)药物市场正处在高速发展阶段,越来越多企业布局推动了细分领域药物可及和市场竞争,尤其国内药企不断取得研发突破,不断向跨国药企产品发起冲击。近日,广东东阳光药业1类创新药磷酸萘坦司韦胶囊获批上市,该药适用于与艾考磷布韦片联用,治疗初治或干扰素经治的基因1、2、3、6型成人慢性丙型肝炎病毒(HCV)感染,可合并或不合并代偿性肝硬化。根据东阳光公开资料,磷酸萘坦司韦(曾用名:磷酸...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.